Madrigal pharmaceuticals announces publication in the lancet of positive phase 2 results for resmetirom (mgl-3196) for the treatment of non-alcoholic steatohepatitis (nash)

Data from this 36-week, multicenter, randomized, double-blind, placebo-controlled phase 2 clinical trial in patients with nash:

MDGL Ratings Summary

MDGL Quant Ranking